preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.09.20.23295642;](https://doi.org/10.1101/2023.09.20.23295642) this version posted September 26, 2023. The copyright holder for this

It is made available under a [CC-BY-NC 4.0 International license](http://creativecommons.org/licenses/by-nc/4.0/) .

<sup>1</sup>**Metabolic health tracking using Ultrahuman M1 continuous glucose monitoring** 

#### <sup>2</sup>**platform in non- and pre-diabetic Indians: a multi-armed observational study**

- **Authors:** Monik Chaudhry<sup>1</sup> Mohit Kumar<sup>1,2</sup> Vatsal Singhal<sup>1,2</sup> and Bhuvan Srinivasan<sup>1,3</sup>
- <sup>4</sup>**Affiliations:**
- <sup>5</sup>1-Ultrahuman Healthcare Private Limited, Bangalore, Karnataka, India
- <sup>6</sup>2- Equal author
- <sup>7</sup>3- Corresponding author
- 

#### <sup>9</sup>**Corresponding Author**

10 Bhuvan Srinivasan

- 11 Ultrahuman Healthcare Private Limited,
- 12 No. 799, V K Paradise Sector2, HSR Layout Bengaluru
- 13 Karnataka, Bengaluru, India 560102
- <sup>14</sup>Email: bhuvan@ultrahuman.com
- 15

### <sup>16</sup>**Abstract**

- <sup>17</sup>**Background:** CGM-based tracking is expanding in non-diabetic groups to meet wellness and
- 18 preventive care needs. However, data is limited on short-term outcomes for glycemic control,
- 19 insulin resistance and correlation of algorithm-derived score to known glycemic metrics in
- 20 controlled settings, making benchmarking difficult. This is especially true for the high-risk
- 21 Indian/South Asian demographic.

22 **Objectives**: To examine changes resulting from the Ultrahuman (UH) M1 CGM application-

- 23 with concomitant FitBit tracker use in patterns of glucose variability (GV). Evaluate GV
- 24 correlations with stress, sleep duration, inflammation, and activity. Examine correlations
- 25 between UH metabolic score (UH-MS) and biomarkers of dysglycemia and insulin
- 26 resistance.

It is made available under a [CC-BY-NC 4.0 International license](http://creativecommons.org/licenses/by-nc/4.0/) . medRxiv preprint doi: [https://doi.org/10.1101/2023.09.20.23295642;](https://doi.org/10.1101/2023.09.20.23295642) this version posted September 26, 2023. The copyright holder for this<br>preprint (which was not certified by peer review) is the author/funder, who has grant



It is made available under a [CC-BY-NC 4.0 International license](http://creativecommons.org/licenses/by-nc/4.0/) .

### **Introduction**



It is made available under a [CC-BY-NC 4.0 International license](http://creativecommons.org/licenses/by-nc/4.0/) .



It is made available under a [CC-BY-NC 4.0 International license](http://creativecommons.org/licenses/by-nc/4.0/) . medRxiv preprint doi: [https://doi.org/10.1101/2023.09.20.23295642;](https://doi.org/10.1101/2023.09.20.23295642) this version posted September 26, 2023. The copyright holder for this<br>preprint (which was not certified by peer review) is the author/funder, who has grant



preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.09.20.23295642;](https://doi.org/10.1101/2023.09.20.23295642) this version posted September 26, 2023. The copyright holder for this

It is made available under a [CC-BY-NC 4.0 International license](http://creativecommons.org/licenses/by-nc/4.0/) .

#### <sup>113</sup>**Methods**

#### <sup>114</sup>*Study design and participants*

<sup>115</sup>This prospective two-arm parallel-group observational study was conducted across multiple

- 116 urban diabetes clinics and hospitals  $(N=9)$  across the states of Delhi, Karnataka, Telangana,
- <sup>117</sup>Gujarat, and Tamil Nadu within India. Following this, participants were recruited in an

118 enrolment period that spanned from September 2022 to December 2022.

- 119 The overarching aim of this study was to assess CGM-derived GV indices and their
- 120 correlation with clinical biomarkers in healthy and pre-diabetic individuals to generate
- <sup>121</sup>reference data on metabolic health for this age and geographic group. The dataset would also
- 122 be used to a) investigate MS correlation with well-established clinical biomarkers of stress,

<sup>123</sup>sleep, inflammation, insulin resistance, and glucose intolerance, and b) form the basis of

124 updating MS. MS is a proprietary algorithmic output that has been developed by Ultrahuman

125 Pvt Ltd., for the purpose of metabolic fitness tracking and management.<sup>16</sup>

126 Participants (males and females) were included in the study if they were between 25-50 years

127 of age (both inclusive) and had body mass index (BMI) within  $20 - 30$  kg/m<sup>2</sup> range. They

128 were required to comply with the advised use of CGM (Abbott FreeStyle Libre<sup>22</sup>, activity

129 tracker (Fitbit Inspire 2), and the UH Application. The exclusion criteria consisted of a

130 history of acute or subacute infection (within the last three months) and chronic illnesses

<sup>131</sup>(including T1 (Type 1)- and T2DM, and cardiac disease), anemia, endocrine disorders, and

132 autoimmune conditions. Individuals taking antimicrobials, including antibiotics, antivirals,

133 and antifungals were also ineligible for participation.

134 The study was conducted in compliance with the International Conference of

- <sup>135</sup>Harmonization/Good Clinical Practice guidelines (ICH-GCP) and the Declaration of
- <sup>136</sup>Helsinki. Participants voluntarily signed a written informed consent form prior to
- 137 participation and were allowed to withdraw from the study at any time. The study protocol

<sup>138</sup>was reviewed and approved by the ethics committees of all the participating centers. Ethics 139 clearance was secured individually at each site involving either the hospital's ethics 140 committee or an independently instituted ethics committee for smaller clinics. The details of 141 the trial site, ethics committee, and date of approval are provided in a tabular format in <sup>142</sup>**Supplementary Table 7**. This study is registered in the Clinical Trials Registry - India 143 CTRI/2022/08/044808.

144

#### <sup>145</sup>*Study procedure*

146 Random sampling method was used to recruit eligible subjects. During the screening visit

147 (between -3 to -1 day from the baseline [inclusion] visit), a detailed medical, medication-

<sup>148</sup>related, and family history was acquired. Demographic data, anthropometric measurements,

149 and vital signs were recorded and blood samples were obtained to estimate FBG, and

<sup>150</sup>glycated HbA1c levels. Potential participants also underwent an OGTT test. Based on the

151 results obtained, the subjects were then screened for eligibility and those selected were

152 divided into two groups: healthy/non-diabetic (FBG: 79-99 mg/dl; HbA1c: 4.0-5.6 % and 2-

153 hour plasma glucose during 75-g OGTT below 140 mg/dL) and pre-diabetics (FBG: 100-125

<sup>154</sup>mg/dl; HbA1c: 5.7-6.4 % and 2-hour plasma glucose during 75-g OGTT: 140–199 mg/dL)

155 based on the ADA criteria of Screening and Diagnostic Tests for Prediabetes.<sup>7</sup>

156

157 At day 0 (baseline visit), the eligibility was reconfirmed by repeating the OGTT and a general

158 physical examination. Details regarding the CGM and UH-M1 application were also

159 explained to the participants during this visit. The app was installed on the smartphone of the

160 subject, and he/she was trained on the features of the app and its use. Once the subject was

161 familiar with the app, the CGM was attached to the upper arm (preferably left) and activated

162 followed by the initializing of the app. The participants were asked to follow a regular daily



### *Study endpoints:*

- 181 The primary endpoints included CGM-based glucose indices over 14 days period such as the
- 182 mean glucose levels as described by a 24-hour profile during 2 weeks; time in glucose ranges
- 183 (TIR: 70-180 mg/dL for "acceptable" diabetes glucose range; TAR: time-above-range >180
- 184 mg/dL and TBR: time-below-range <70 mg); GV as measured by the standard deviation (SD)
- 185 and the coefficient of variation (CV); and the mean amplitude of glycaemic excursions
- 186 (MAGE), defined as the arithmetic mean of the amplitude of glucose excursions that are
- 187 greater than the standard deviation of the glucose values. In addition, for the

<sup>188</sup>preventive/wellness use case, the UH-CGM application employs a tighter target range of 70- <sup>189</sup>110mg/dL; and hence it was also computed for the healthy and pre-diabetic groups post-facto 190 after study completion. Daily MS scores were generated for each participant across the study 191 period which were then used for correlation analyses (representative snapshot of MS display 192 on the app interface is depicted in Supplementary Figure S1). 193 The secondary endpoints included changes in FBG levels from day 0 -15, the correlation 194 between GV indices and sleep duration, step count, heart rate (acquired from fitness tracker <sup>195</sup>use), and blood-based biomarkers such as stress (serum cortisol), inflammation (serum Hs-C 196 reactive protein (Hs-CRP)). Additional samples to catalog gut microbiome, and urine 197 metabolites were also acquired for future analyses and are not within the scope of this 198 manuscript.

#### <sup>200</sup>*Statistical analysis:*

201 Data were analyzed between day 2-14 of CGM use to rule out differences in sensor 202 application across participants and known variability of sensor output in the first 24h of 203 sensor activation<sup>24</sup>. Data were analyzed using the R Software version 4.2.2<sup>25</sup> Intent-to-Treat <sup>204</sup>(ITT) set (included all subjects who were enrolled in the study) and Per Protocol (PP) set <sup>205</sup>(included all subjects who completed the study procedures as per the planned protocol) were 206 defined for analyzing the data. Normality tests were performed to select the appropriate test 207 and the outliers were removed following +3SD for normal distributions, and beyond three 208 times lowest and highest interquartile range (IQR) for non-parametric data. Categorical data 209 were presented as frequencies and proportions and compared using the Chi-square test with 210 Yates correction or Fischer's exact t-test, as appropriate. Continuous data were presented as 211 mean with SD or median with interquartile range and were compared using unpaired t-test, or 212 Mann-Whitney U test, as appropriate. In addition to summary statistics, the differences in the

It is made available under a [CC-BY-NC 4.0 International license](http://creativecommons.org/licenses/by-nc/4.0/) .



It is made available under a [CC-BY-NC 4.0 International license](http://creativecommons.org/licenses/by-nc/4.0/) .

#### **Results**

#### 224 Patient disposition and trends



It is made available under a [CC-BY-NC 4.0 International license](http://creativecommons.org/licenses/by-nc/4.0/) .



271 diabetics over time

It is made available under a [CC-BY-NC 4.0 International license](http://creativecommons.org/licenses/by-nc/4.0/) .



It is made available under a [CC-BY-NC 4.0 International license](http://creativecommons.org/licenses/by-nc/4.0/) .

# 296 Secondary outcomes: Correlation of CGM-derived glycemic metrics with biomarkers

#### 297 associated with metabolic syndrome



320 correlations. There was a significant positive correlation between ADRR, MODD, and

preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.09.20.23295642;](https://doi.org/10.1101/2023.09.20.23295642) this version posted September 26, 2023. The copyright holder for this

It is made available under a [CC-BY-NC 4.0 International license](http://creativecommons.org/licenses/by-nc/4.0/) .

**321** step count in non-diabetics (**Supplementary Table S5, Figure 3E**), while heart rate was 322 positively correlated with ADRR and MAGE in pre-diabetics (**Supplementary Table 5,** <sup>323</sup>**Figure 3F**).

#### 324 Correlations with CGM-derived GV indices with HOMA-IR, OGTT, and HbA1c

<sup>325</sup>While CGM-derived indices have been utilized to develop algorithms to differentiate 326 between healthy and diabetic individuals, studies evaluating the correlation of CGM-327 derived GV metrics with clinical gold standards to detect impaired glucose tolerance 328 (IGT) and insulin resistance such as HbA1c, OGTT, and HOMA-IR are scarce.<sup>31-33</sup> To 329 bridge this gap, we carried out a post-hoc analysis, correlating the factors recorded in our 330 study **(Table 1)**. For all clinical biomarkers, daily glycemic variability (J-index) was a 331 strong associate in the pre-diabetes group with highly significant positive correlations. <sup>332</sup>The HBGI count in both healthy and pre-diabetics was a consistent measure of elevated 333 OGTT and HbA1c levels. However, HBGI correlated with increased HOMA IR showing <sup>334</sup>that insulin resistance is a feature of IGT space and not a healthy glucose control space. <sup>335</sup>LBGI showed some interesting correlations with OGTT and HOMA-IR in the healthy 336 group, perhaps indicating that hypoglycemic events requiring glucose mobilization are <sup>337</sup>more tightly regulated in normal glucose tolerance regimes. Specifically, in healthy 338 participants, the glucose swing as captured by the ADRR or MODD is likely a better 339 predictor of nascent insulin resistance. In summary, there is a difference in the type of <sup>340</sup>glycemic parameters that a healthy or an IGT user of CGMs should focus on. <sup>341</sup>Correlations of MS with biomarkers associated with metabolic syndrome and fitness metrics 342 The MS metric was developed as an all-encompassing snapshot of glucose tolerance and 343 by extension, of the glycemic fitness of UH-M1 users. While this proprietary score is <sup>344</sup>composed of weighted contributions from an individual's glycemic variability, time in

<sup>345</sup>range, and mean glucose values, we tested the correlation of MS with the clinical

It is made available under a [CC-BY-NC 4.0 International license](http://creativecommons.org/licenses/by-nc/4.0/) .



 $b^2$  364 be increasing.<sup>19-20</sup> To our knowledge, this is the first study that provides CGM-derived

365 guidance values of glycemic indices and variability in non-diabetic (healthy) and pre-diabetic

366 Indian populations. Furthermore, our extended analyses revealed that of the multiple

367 glycemic indices used in this therapy area, there is a difference in the significance of

- 368 correlating benchmarks of glucose control like Hba1c, OGTT, and insulin resistance by
- HOMA-IR between healthy and pre-diabetics. Interestingly, UH-MS mirrors many of the
- trends in glycemic dysfunction found in pre-diabetics and offers a dynamic, easy-to-

It is made available under a [CC-BY-NC 4.0 International license](http://creativecommons.org/licenses/by-nc/4.0/) .



mean glucose levels between non-diabetics and pre-diabetics with no significant differences

395 in TIR per the broader ADA guideline range. Interestingly, the rTIR per app guidance of a



It is made available under a [CC-BY-NC 4.0 International license](http://creativecommons.org/licenses/by-nc/4.0/) .



446 world cohorts to determine the best continuous proxies for clinical biomarkers of glucose

447 dysfunction.

<sup>448</sup>Wellness/risk score calculators offer an easy-to-understand metric for laypeople to appreciate 449 the risk of developing various conditions. Scores such as the Life's Essential 8<sup>TM</sup> developed 450 by the American Heart Association predict cardiovascular health based on self-reported <sup>451</sup>responses to generalized questions and offer a demographic risk factor-powered perspective 452 to an individual's heart health.  $46$  On the other hand, personalized wearables and digital health 453 monitoring devices are accompanied by aggregate, algorithmic scores to serve as an easy-to-454 understand handle for a user to track his/her health and potentially modify their behaviour. <sup>455</sup>Only a handful of these scores have been validated using cohorts in controlled settings and 456 benchmarked to accepted clinical biomarkers. To our knowledge, our study is novel in its <sup>457</sup>approach to clinically validate UH-MS and the results indicate that the score is an effective <sup>458</sup>digital proxy for IGT and insulin resistance in the population studied. Given its relevance to <sup>459</sup>glucose tolerance and insulin resistance, it is plausible to imagine an expanded use case in 460 other ethnic groups.

461 The main limitation of the study was the short duration of CGM use (14-day period) which 462 may have been minimally sufficient to glean early indications of the positive impact of UH-<sup>463</sup>M1-based tracking. A longer observational study is required to derive more substantive <sup>464</sup>conclusions on app-guided lifestyle changes or the data mining of real-world, non-controlled 465 evidence from the UH user community. Other limitations included capturing basic sleep 466 duration using the Fitbit activity tracker, which did not have refined measurement of epochs, 467 and REM vs. non-REM which could have linked more accurately to GV measured in pre-468 diabetics. This also holds true for opposing correlation patterns of sleep duration with <sup>469</sup>metabolic score. It is not clear how a high MS (indicative of strong glycemic control) is

470 linked with poor sleep in pre-diabetics at the same time that good sleep is coincident with

471 high MS in non-diabetics.



483 the use of MS score as a digital proxy for glycemic health.

#### <sup>485</sup>**Declarations:**

486 Conflicting interests: B.S, V.S., and M.K. are stakeholders in Ultrahuman Healthcare Private Limited.

487 M.C. was a full-time employee of Ultrahuman during the study and analysis period. M.K. and V.S.

488 declare no other conflict of interest. B.S. is a stakeholder of Triomics Healthcare.

489 Funding Statement: The study was sponsored by Ultrahuman Healthcare Pvt. Ltd.

490 Ethical approval: Ethical approval was obtained from each of the clinical trials individually. This is

491 captured in Supplementary Protocol file uploaded and information is available publicly on the Clinical

492 Trial Registry of India website, accessed by trial identifier CTRI/2022/08/044808

- 493 Guarantor: B.S. (ORCID ID: 0009-0009-4865-380X)
- 494 Author Contributions: B.S.: Conceptualization, Methodology, Overall supervision and coordination,
- 495 and manuscript review; M.C.- Trial coordination, Curation of Data, Extended data analysis,
- 496 Visualization, manuscript review; M.K. and V.S.- Conceptualization, Funding acquisition,
- 497 Technological development, and support.
- <sup>498</sup>All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for
- 499 authorship for this article, take responsibility for the integrity of the work, and have given their
- 500 approval for this version to be published.
- 501 Acknowledgments: The authors would like to thank all the participants in the study. Authors are
- 502 grateful to Dr. Prabhat Ranjan Sinha, Dr. R.P. Rajesh, Dr. Neeta Deshpande, Dr. Suresh S.M., Dr.
- 503 Banshi Saboo, Dr. Hamsraj Alva, Dr. B.V.S.N. Raju, Dr. Sriharee Kulkarni, and Dr. Pankaj Aneja
- 504 who were principal investigators at the various trial sites. Additionally, the authors acknowledge the
- 505 contributions of Triomics Healthcare for trial automation and trial management, Dr. Aditi
- 506 Bhattacharya for scientific analyses and publication development support, and Dr. Aafrin Khan for
- 507 editorial support of the manuscript.
- 508 Data availability: Study outcomes data can be made available upon reasonable request. The M1 and
- <sup>509</sup>MS platform codes and technical details are proprietary assets of Ultrahuman and will not be
- 510 disclosed.

# **Tables and Figures**





. [CC-BY-NC 4.0 International license](http://creativecommons.org/licenses/by-nc/4.0/) It is made available under a



The copyright holder for this this version posted September 26, 2023. [;](https://doi.org/10.1101/2023.09.20.23295642) https://doi.101110111012020. ; https://doi.101111012020.09.2020. ; https://doi.2020. ; https://doi.2020. ; https://doi.1011110101111011110101111012012

**Table 2: Correlation Between Metabolic Score and Stress (by Cortisol), Inflammation (by Hs-CRP), HbA1C%, OGTT values, HOMA IR, fasting glucose levels, and fitness variables (PP Population)**



. [CC-BY-NC 4.0 International license](http://creativecommons.org/licenses/by-nc/4.0/) It is made available under a





. [CC-BY-NC 4.0 International license](http://creativecommons.org/licenses/by-nc/4.0/) It is made available under a

**Figure 2. Primary outcome measures in healthy vs. pre-diabetic within the stipulated time-frame** 



**CV: Coefficient of variation; MAGE: Mean amplitude of glycemic excursion; SD: Standard deviation. \*, \*\*, \*\*\* denotes p<0.05, 0.01 and 0.001, by Two -way ANOVA (see text for details)**

. [CC-BY-NC 4.0 International license](http://creativecommons.org/licenses/by-nc/4.0/) It is made available under a

**Figure 3. Secondary outcomes: Correlations of GV with clinical biomarkers associated with impaired glucose tolerance (IGT) and commonly tracked fitness measures** 



**R - correlation coefficient. Linked to Supplementary Tables 2-5** 

. [CC-BY-NC 4.0 International license](http://creativecommons.org/licenses/by-nc/4.0/) It is made available under a

# **Supplementary section**

**Supplementary Figure S1: Exemplar snapshot of the MS information panel on the M1 platform** 



. [CC-BY-NC 4.0 International license](http://creativecommons.org/licenses/by-nc/4.0/) It is made available under a

**Supplementary Figure S2: Restricted time in range in healthy vs pre-diabetic within the stipulated time-frame** 



**rTIR: restricted Time in range, Statistical analyses: Two-factor ANOVA (**cohort x day; main effect, cohort: p<0.0001; main effect, day: p<0.0001, interaction cohort x day: p<0. 0.00001)

. [CC-BY-NC 4.0 International license](http://creativecommons.org/licenses/by-nc/4.0/) It is made available under a



**Supplementary Table S1: Baseline demographics** 

BMI: Body mass index; SD: Standard deviation.

. [CC-BY-NC 4.0 International license](http://creativecommons.org/licenses/by-nc/4.0/) It is made available under a

**Supplementary Table S2: Correlation between Glycaemic variability indices and inflammation (as measured by Hs-CRP) (PP Population)** 



p-value based on Pearson correlation & spearman correlation test

\* represent spearman correlation test

. [CC-BY-NC 4.0 International license](http://creativecommons.org/licenses/by-nc/4.0/) It is made available under a



**Supplementary Table S3: Correlation between glycaemic variability indices and stress (as measured by cortisol) (PP Population)** 

p-value based on Pearson correlation & spearman correlation test

\* represent spearman correlation test

. [CC-BY-NC 4.0 International license](http://creativecommons.org/licenses/by-nc/4.0/) It is made available under a



**Supplementary Table S4: Correlation between Glycaemic variability indices and sleep duration (PP Population)** 

p-value based on Pearson correlation & spearman correlation test

\* represent spearman correlation test

. [CC-BY-NC 4.0 International license](http://creativecommons.org/licenses/by-nc/4.0/) It is made available under a



# **Supplementary Table S5: Correlation between Glycaemic variability indices and physical activity (step count) (PP Population)**

## **Supplementary Table 7: Details of trial sites, principal investigators, ethics committee approval dates**



It is made available under a [CC-BY-NC 4.0 International license](http://creativecommons.org/licenses/by-nc/4.0/) .

#### **References**

1. World health organization-https://www.who.int/health-topics/diabetes#tab=tab\_1 (Accessed 23<sup>rd</sup> July 2023)

2. Yip WCY, Sequeira IR, Plank LD, and Poppitt SD. Prevalence of Pre-Diabetes across Ethnicities: A Review of Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT) for Classification of Dysglycaemia. *Nutrients.* 2017; 22;9(11):1273.

3. Saeedi P, Petersohn I, Salpea P, et al. IDF Diabetes Atlas Committee. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. *Diabetes Res Clin Pract*. 2019;157:107843.

4. Dali-Youcef N, Mecili M, Ricci R, and Andrès E. Metabolic inflammation: connecting obesity and insulin resistance. *Ann Med.* 2013; 45(3):242-53.

5. Fazli GS, Moineddin R, Bierman AS, and Booth GL. Ethnic variation in the conversion of prediabetes to diabetes among immigrant populations relative to Canadian-born residents: a population-based cohort study. *BMJ Open Diabetes Res Care*. 2020; 8(1):e000907.

6. Tuomilehto J, Lindström J, Eriksson JG, et al. Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. *N Engl J Med.* 2001; 344(18):1343-50.

7. Prevention or Delay of Type 2 Diabetes: Standards of Medical Care in Diabetes—2021. American Diabetes Association. Diabetes J. Diabetes Care 2021;44(Supplement\_1):S34–S39

8. Duan D, Kengne AP, and Echouffo-Tcheugui JB. Screening for Diabetes and Prediabetes. *Endocrinol Metab Clin North Am.* 2021; 50(3):369-385.

9. Bergman M, Abdul-Ghani M, DeFronzo RA, et al. Review of methods for detecting glycemic disorders. *Diabetes Res Clin Pract*. 2020; 165:108233.

10. Rodbard D. Continuous Glucose Monitoring: A Review of Successes, Challenges, and Opportunities. *Diabetes Technol Ther.* 2016; 18 Suppl 2(Suppl 2):S3-S13.

11. Soliman A, DeSanctis V, Yassin M, et al. Continuous glucose monitoring system and new era of early diagnosis of diabetes in high risk groups. *Indian J Endocrinol Metab*. 2014; 18(3):274-82.

12. Klonoff DC, Nguyen KT, Xu NY, et al. Use of Continuous Glucose Monitors by People Without Diabetes: An Idea Whose Time Has Come? J Diabetes Sci Technol. 2022; doi: 10.1177/19322968221110830.

13. Daly A, and Hovorka R. Technology in the management of type 2 diabetes: Present status and future prospects. *Diabetes Obes Metab*. 2021; 23(8):1722-1732.

15. https://blog.ultrahuman.com/blog/beginners-guide-to-the-ultrahuman-m1/ (accessed 23rd July 2023)

16. https://blog.ultrahuman.com/blog/how-is-your-metabolic-score-calculated/ (Accessed 13<sup>th</sup> August 2023)

17. Mohan V, Joshi S, Mithal A, et al. Expert Consensus Recommendations on Time in Range for Monitoring Glucose Levels in People with Diabetes: An Indian Perspective. Diabetes Ther. 2023; 14(2):237-249.

18. Wells JC, Pomeroy E, Walimbe SR, et al. The Elevated Susceptibility to Diabetes in India: An Evolutionary Perspective. *Front Public Health*. 2016; 4:145.

19. Anjana RM, Unnikrishnan R, Deepa M, et al. ICMR-INDIAB Collaborative Study Group. Metabolic noncommunicable disease health report of India: the ICMR-INDIAB national cross-sectional study (ICMR-INDIAB-17). *Lancet Diabetes Endocrinol*. 2023; 11(7):474-489.

preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.09.20.23295642;](https://doi.org/10.1101/2023.09.20.23295642) this version posted September 26, 2023. The copyright holder for this

It is made available under a [CC-BY-NC 4.0 International license](http://creativecommons.org/licenses/by-nc/4.0/) .

20. Anjana RM, Deepa M, Pradeepa R et al. ICMR–INDIAB Collaborative Study Group. Prevalence of diabetes and prediabetes in 15 states of India: results from the ICMR-INDIAB population-based cross-sectional study. *Lancet Diabetes Endocrinol*. 2017; 5(8):585-596.

21. Anjana RM, Shanthi Rani CS, et al. Incidence of Diabetes and Prediabetes and Predictors of Progression Among Asian Indians: 10-Year Follow-up of the Chennai Urban Rural Epidemiology Study (CURES). *Diabetes Care*. 2015; 38(8):1441-8.

22. https://www.accessdata.fda.gov/cdrh\_docs/pdf19/K193371.pdf (Accessed 21st July 2023)

23. Buysse DJ, Reynolds CF 3rd, Monk TH, et al. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. *Psychiatry Res.* 1989; 28(2):193-213.

 24. Bailey T, Bode BW, Christiansen MP, et al. The Performance and Usability of a Factory-Calibrated Flash Glucose Monitoring System. *Diabetes Technol Ther*. 2015; 17(11):787-94.

25. https://www.R-project.org. R Core Team (2021). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. (Accessed March 2023).

 26. Battelino T, Danne T, Bergenstal RM, et al. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations from the International Consensus on Time in Range. *Diabetes Care.* 2019; 42(8):1593-1603.

27. Hill NR, Oliver NS, Choudhary P, et al. Normal reference range for mean tissue glucose and glycemic variability derived from continuous glucose monitoring for subjects without diabetes in different ethnic groups. *Diabetes Technol Ther.* 2011; 13(9):921-8.

28. Jaiswal A, Tabassum R, Podder A, et al. Elevated level of C-reactive protein is associated with risk of prediabetes in Indians. *Atherosclerosis*. 2012; 222(2):495-501.

29. Sonnier T, Rood J, Gimble JM, and Peterson CM. Glycemic control is impaired in the evening in prediabetes through multiple diurnal rhythms. *J Diabetes Complications*. 2014; 28(6):836-43.

30. Hur MH, Lee MK, Seong K, and Hong JH. Deterioration of Sleep Quality According to Glycemic Status. *Diabetes Metab J*. 2020; 44(5):679-686.

31. Mishra A, Podder V, Modgil S, et al. Higher Perceived Stress and Poor Glycemic Changes in Prediabetics and Diabetics Among Indian Population. *J Med Life*. 2020;13(2):132-137.

32. Satya Krishna SV, Kota SK, Modi KD. Glycemic variability: Clinical implications. *Indian J Endocrinol Metab.* 2013;17(4):611-9.

33. Acciaroli G, Sparacino G, Hakaste L, et al. Diabetes and Prediabetes Classification Using Glycemic Variability Indices From Continuous Glucose Monitoring Data. *J Diabetes Sci Technol*. 2018;12(1):105-113.

34. main.mohfw.gov.in/sites/default/files/NFHS-5\_Phase-II\_0.pdf (Accessed 22nd July 2023)

35. Jain AB. Glycemic improvement with a novel interim intervention technique using retrospective professional continuous glucose monitoring (GLITTER study): A study from Mumbai, India. *Diabetes Metab Syndr.* 202;15(3):703-709.

36. Shamanna P, Saboo B, Damodharan S, et al. Reducing HbA1c in Type 2 Diabetes Using Digital Twin Technology-Enabled Precision Nutrition: A Retrospective Analysis. *Diabetes Ther.* 2020; 11(11):2703-2714.

37. Anjana RM, Kesavadev J, Neeta D, et al. Multicenter Real-Life Study on the Effect of Flash Glucose Monitoring on Glycemic Control in Patients with Type 1 and Type 2 Diabetes. *Diabetes Technol Ther*. 2017; 19(9):533-540.

preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.09.20.23295642;](https://doi.org/10.1101/2023.09.20.23295642) this version posted September 26, 2023. The copyright holder for this

It is made available under a [CC-BY-NC 4.0 International license](http://creativecommons.org/licenses/by-nc/4.0/) .

 38. Ranjani H, Nitika S, Anjana R, et al. Impact of noncommunicable disease text messages delivered via an app in preventing and managing lifestyle diseases: results of the myArogya worksite-based effectiveness study from India. *J Diabetol.* 2020; 11: 90–100.

39. Pfammatter A, Spring B, Saligram N, et al. mHealth Intervention to Improve Diabetes Risk Behaviors in India: A Prospective, Parallel Group Cohort Study. *J Med Internet Res*. 2016; 18(8):e207. doi: 10.2196/jmir.5712.

40. Dehghani Zahedani A, Shariat Torbaghan S, Rahili S, et al. Improvement in Glucose Regulation Using a Digital Tracker and Continuous Glucose Monitoring in Healthy Adults and Those with Type 2 Diabetes. *Diabetes Ther.* 2021;12(7):1871-1886.

41. Zand A, Ibrahim K, Patham B. Prediabetes: Why Should We Care? *Methodist Debakey Cardiovasc J.* 2018; 14(4):289-297.

42. Kamath DY, Xavier D, Sigamani A, and Pais P. High sensitivity C-reactive protein (hsCRP) & cardiovascular disease: An Indian perspective. *Indian J Med Res.* 2015; 142(3):261-8.

43. Ghule A, Kamble TK, Talwar D, et al. Association of Serum High Sensitivity C-Reactive Protein With Prediabetes in Rural Population: A Two-Year Cross-Sectional Study. *Cureus.* 2021;13(10):e19088. doi: 10.7759/cureus.19088.

44. El Fatouhi D, Héritier H, Allémann C, et al. Associations Between Device-Measured Physical Activity and Glycemic Control and Variability Indices Under Free-Living Conditions. *Diabetes Technol Ther.* 2022; 24(3):167-177.

45. Longato E, Acciaroli G, Facchinetti A, et al. Simple Linear Support Vector Machine Classifier Can Distinguish Impaired Glucose Tolerance Versus Type 2 Diabetes Using a Reduced Set of CGM-Based Glycemic Variability Indices. *J Diabetes Sci Technol*. 2020; 14(2):297-302.

46. https://www.heart.org/en/healthy-living/healthy-lifestyle/lifes-essential-8. (Accessed 13<sup>th</sup> August 2023)